RxDoctor Payments DataLook up a doctor →

Allison Rosenthal, DO

Hematology & Oncology · Scottsdale, AZNPI 1255568135

Payments from drug & device makers

$646,211in general payments, 2019–2025

Across 77 payments — averaging $8392.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$445K
  • Jazz Pharmaceuticals Inc.$106K
  • Genmab U.S., Inc.$24K
  • Novartis$21K
  • Eli Lilly$19K
  • Genmab A/s$15K
  • plus $16K from 10 others

What the payments were for

  • Food & beverage$64798%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$646,211 in reported general payments places this provider in the 75th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$2,715,841
Medicare patients
648
Services billed
88,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib12$274,054
BrukinsaZanubrutinib22$266,251
RevlimidLenalidomide14$252,141
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$53,030
XareltoRivaroxaban18$14,114
EliquisApixaban11$6,485
Entecavir16$3,155
Acyclovir96$1,636
Ondansetron Hcl46$834
Prochlorperazine Maleate42$472
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim27$351
Gabapentin14$101
Prednisone25$71
Lorazepam11$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$444,976$252,14114 claims
Johnson & JohnsonXarelto$238$14,11418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 261 hematology & oncology providers in Arizona.

Other hematology & oncology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →